Marshall Wace’s Phathom Pharmaceuticals PHAT Stock Holding History

Marshall Wace’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.23M	Sell	666,090 -194,602	-23%	-$2.22M	0.01%	1189
2026 Q1	$9.56M	Buy	+860,692	New	+$10.9M	0.01%	1000
2025 Q2	–	Sell	-314,873	Closed	-$1.97M	–	3049
2025 Q1	$1.97M	Buy	314,873 +216,805	+221%	+$1.32M	﹤0.01%	1466
2024 Q4	$796K	Buy	+98,068	New	+$1.21M	﹤0.01%	1837
2024 Q3	–	Sell	-112,691	Closed	-$1.16M	–	2855
2024 Q2	$1.16M	Buy	+112,691	New	+$1.16M	﹤0.01%	1622
2023 Q2	–	Sell	-37,096	Closed	-$265K	–	2866
2023 Q1	$265K	Buy	+37,096	New	+$326K	﹤0.01%	2337
2022 Q3	–	Sell	-54,769	Closed	-$462K	–	3693
2022 Q2	$462K	Buy	54,769 +30,417	+125%	+$313K	﹤0.01%	2822
2022 Q1	$330K	Sell	24,352 -7,813	-24%	-$126K	﹤0.01%	2938
2021 Q4	$632K	Buy	+32,165	New	+$757K	﹤0.01%	2684
2021 Q3	–	Sell	-29,731	Closed	-$1.01M	–	3331
2021 Q2	$1.01M	Sell	29,731 -84,154	-74%	-$3.01M	﹤0.01%	1801
2021 Q1	$4.28M	Sell	113,885 -4,764	-4%	-$199K	0.02%	922
2020 Q4	$3.94M	Buy	+118,649	New	+$4.81M	0.02%	661

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Marshall Wace's PHAT Position: Q2 2026 in Review

Marshall Wace reduced its Phathom Pharmaceuticals (PHAT) stake by 23% in Q2 2026, selling an estimated $2.22M and leaving 666,090 shares worth $7.23M. The position accounts for 0.01% of the portfolio, ranked #1189.

Marshall Wace first reported a position in PHAT in Q4 2020 and has held it in 12 quarters since. The position peaked at $9.56M in Q1 2026. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

Marshall Wace held 666,090 shares of Phathom Pharmaceuticals worth $7.23M as of Q2 2026.
Marshall Wace sold 194,602 Phathom Pharmaceuticals shares in Q2 2026, an estimated $2.22M.
Phathom Pharmaceuticals made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #1189 holding.
Marshall Wace first reported a position in Phathom Pharmaceuticals in Q4 2020 and has held it in 12 quarters since.
Marshall Wace's Phathom Pharmaceuticals position peaked at $9.56M in Q1 2026.
162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.